Seattle Genetics (SGEN), Takeda Announce Completion of ADCETRIS Phase 3 Enrollment in rontline Mature T-cell Lymphoma
Go back to Seattle Genetics (SGEN), Takeda Announce Completion of ADCETRIS Phase 3 Enrollment in rontline Mature T-cell Lymphoma| Seattle Genetics Inc /wa (NASDAQ: SGEN) | Delayed: 228.74 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $228.74 | 52 Week High | $75.36 | |||
| Open | $228.74 | 52 Week Low | $26.02 | |||
| Day High | $228.74 | P/E | N/A | |||
| Day Low | $228.74 | EPS | $-0.51 | |||
| Volume | 1,377,869 | |||||
| Takeda Pharmaceutical Co Ltd Sponsored ADR (AMEX: TKPYY) | Delayed: 16.59 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $16.59 | 52 Week High | $25.72 | |||
| Open | $37.62 | 52 Week Low | $20.32 | |||
| Day High | $16.59 | P/E | N/A | |||
| Day Low | $16.59 | EPS | $0.00 | |||
| Volume | 0 | |||||
